We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00473824
Recruitment Status : Terminated (New sponsor's decision to pursue a redesigned clinical study)
First Posted : May 16, 2007
Results First Posted : February 7, 2012
Last Update Posted : March 10, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) [Civacir(TM)] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.

Condition or disease Intervention/treatment Phase
Sequelae of Viral Hepatitis Transplantation Infection Evidence of Liver Transplantation Biological: Hepatitis C Immune Globulin Intravenous (Human) 5% Phase 2

Detailed Description:

Hepatitis C virus (HCV) infection is the leading single cause of liver transplantation (LT) in the US and Europe. Recurrence of HCV infection following LT is almost universal. There is currently no effective way to prevent post-transplantation HCV infection of the liver graft and related progression of HCV-related liver disease. This study is designed to evaluate a polyclonal human hepatitis C immune globulin (Civacir) given during and post liver transplantation for preventing or reducing the impact of recurrent HCV infection.

In this open-label trial, 2 subjects will be randomized to receive Civacir (standard of care treatment plus Civacir) for every 1 Control subject (standard of care treatment alone). Civacir recipients will receive 18 intravenous infusions over 24 weeks beginning at the time of liver transplantation.

Viral loads, liver enzyme assessments and liver biopsy assessments will be made at scheduled intervals during the study which will last for 48 weeks.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients
Study Start Date : May 2007
Primary Completion Date : February 2009
Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Rhophylac
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Civacir Treated
Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
Biological: Hepatitis C Immune Globulin Intravenous (Human) 5%
Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
Other Name: Civacir™
No Intervention: Observational Control
Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].


Outcome Measures

Primary Outcome Measures :
  1. Post Transplant Reduction in Viral Load (as Measured Quantitatively by Hepatitis C Virus (HCV) Reverse Transcription-Polymerase Chain Reaction (HCV RT-PCR)). [ Time Frame: Outcome evaluations at 1 month (Day 28) and 6 months ( 24 weeks) post-tranplant. ]
    Proportion of subjects who achieve reduction in viral load from the baseline pre-transplant value. Baseline is the pre-transplant HCV viral load as measeured by RT-PCR. Post-transplant HCV viral load is determined at both 1 month and 6 months post-tranplant.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, 18 to 75 years of age.
  • Written informed consent.
  • Expectation of compliance with the protocol procedures.
  • If female, have a negative pregnancy test within 3 days prior to randomization and use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.
  • HCV infection identified by positive, quantifiable HCV-RNA test within 3 months prior to transplantation.
  • First time liver transplant recipient.
  • Primary, single organ recipient (deceased donor <65 years of age).
  • Normal TSH.
  • Subjects with a pre-LT diagnosis of hepatocellular carcinoma (HCC) may be enrolled provided: there is no evidence of extrahepatic spread, tumor is solitary and <5cm or there are up to three tumors <3 cm.
  • Agree to receive study medication as outlined in the protocol and follow all study related procedures until the conclusion of their protocol participation.
  • Agree to consume no alcohol during the entire study period.

Exclusion Criteria:

  • Has received an investigational agent within the last six weeks prior to liver transplantation. Exceptions include Theraspheres for hepatocellular carcinoma or rifaximin.
  • Known immunoglobulin A deficiency.
  • Subject weighs more than 112.5 Kg (248 pounds).
  • Known history of cancer, suspected cancer, or cancer therapy within 12 months prior to the administration of the investigational product, except for treatment for basal cell carcinoma, squamous cell carcinoma, cancer of the cervix in situ, early stage prostate cancer (Gleason's grade 1 or 2), or a history of malignancy where the risk of recurrence is >= 20% within 2 years. A significant exception is hepatocellular carcinoma with predefined acceptability (see inclusion criteria).
  • Has any condition judged by the study physician to preclude participation in the study, including any psychological disorder, which might hinder compliance.
  • History of use of immunosuppressive or immunomodulatory drugs within 3 months prior to randomization (except low-dose physiologic replacement glucocorticoid therapy (<=10 mg of prednisone or equivalent per day).
  • Recipient of liver from a living donor.
  • Subjects whose liver is obtained from a non-beating heart donor.
  • Subjects scheduled to receive a split liver transplantation.
  • Liver transplants that were obtained from donors across ABO incompatible blood type.
  • Donor liver cold ischemic time greater than 20 hours.
  • Donor liver is from a hepatitis C positive donor.
  • Evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment.
  • Serum creatinine level >2.0 times the upper limit of normal or advanced renal disease at screening.
  • Neutrophil count <1500 cells/mm3, WBC>20,000 x 109/L, Hgb <8 g/dL, or platelet count <25,000 cells/mm3.
  • Planned use of T-cell depleting antibody therapies.
  • Hepatitis B (sAg, cAb IgM), hepatitis A (IgM) or HIV infection.
  • History of autoimmune disease (SLE, scleroderma, RA, etc.).
  • Women who are pregnant or breast feeding.
  • The use of colony stimulating factor agents to facilitate subject's entry into study within 2 weeks of enrollment.
  • History of severe psychiatric disease, especially depression.
  • Seizure disorders uncontrolled by anticonvulsants (within the last 12 mos).
  • History of severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant medical disease that would put the subject at risk from the volume of the infusions or significant risk of bleeding from the underlying condition.
  • Evidence of alcohol and/or drug abuse within 6 months of entry or inability/unwilling-ness to abstain from alcohol throughout entire course of treatment and follow-up.
  • Concomitant medication with rifabutin, pyrazinamide, isoniazid, thalidomide, oxymetholone (Anadrol).
  • History of thyroid disease poorly controlled on prescribed medications.
  • History or other evidence of severe illness or any other conditions which would make the subject, in the opinion of the investigator, unsuitable for Civacir treatment.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473824


Locations
United States, Arizona
Mayo Clinic
Phoenix, Arizona, United States, 85054
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Biotest Pharmaceuticals Corporation
Investigators
Study Director: Eliezer Katz, MD Clinical Trial and Consulting Services
Study Director: Shailesh Chavan, MD Biotest Pharmaceuticals
More Information

Responsible Party: Biotest Pharmaceuticals Corporation
ClinicalTrials.gov Identifier: NCT00473824     History of Changes
Other Study ID Numbers: Nabi-3104
First Posted: May 16, 2007    Key Record Dates
Results First Posted: February 7, 2012
Last Update Posted: March 10, 2017
Last Verified: May 2012

Keywords provided by Biotest Pharmaceuticals Corporation:
hepatitis C
liver transplantation
immune globulin

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Immunoglobulins
Antibodies
gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs